In vitro antiviral activity of resveratrol against respiratory viruses

Journal of Chemotherapy

Volumn 20, Issue 3, 2008, Pages 393-394

  Drago, L ^a   Nicola, L ^a   Ossola, F ^a   De Vecchi, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL;

ADENOVIRUS; ANTIVIRAL ACTIVITY; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG POTENCY; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A; LETTER; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS STRAIN;

EID: 47349091605     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.3.393     Document Type: Letter

References (27)

1. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin. Biochem 1997; 30 (2): 91-113
2. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Eno Vitic 1992; 43 (1): 49-52
3. Jang M, Cai L, Udeani GO et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275 (5297): 218-220
4. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52 (4): 673 751.
5. Ferguson LR. Role of plant polyphenols in genomic stability. Mutat Res 2001; 475 (1-2): 89 111.
6. Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 2002; 71 (6): 655-665
7. Wang Q, Xu J, Rottinghaus GE et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002; 958 (2): 439-447
8. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 2004; 22 (3): 169-188.
9. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425 (6954): 191-196.
10. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a shortlived vertebrate. Curr Biol 2006; 16 (3): 296-300.
11. Fuhrman B, Volkova N, Coleman R, Aviram M. Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. J Nutr. 2005; 135(4): 722-728.
12. Stojanovic S, Sprinz H, Brede O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 2001; 391 (1): 79-89.
13. Higami Y, Barger JL, Page GP, et al. Energy restriction lowers the expression of genes linked to inflammation, the cytoskeleton, the extracellular matrix, and angiogenesis in mouse adipose tissue. Nutr. 2006;136 (2): 343-352.
14. Wood JG, Rogina B, Lavu S et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430 (7000): 686-689.
15. Palamara AT, Nencioni L, Aquilano K et al. Inhibition of influenza A virus replication by resveratrol. J Infect Dis 2005; 191 (10): 1719-1729.
16. Ragione FD, Cucciolla V, Borriello A, et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 1998; 250 (1): 53-58.
17. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci. 2004; 93 (10): 2448-2457.
18. Docherty JJ, Sweet TJ, Bailey E, Faith SA, Booth T. Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res 2006; 72 (3): 171-177.
19. Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ. Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells. Antiviral Res 2006; 72 (3): 242-251.
20. Cotarelo M, Catalan P, Sanchez-Carrillo C et al. Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents. J Antimicrob Chemother 1999; 44 (5): 705-708.
21. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 1999; 43 (3): 145-155.
22. Evers DL, Wang X, Huong SM, Huang DY, Huang ES. 3,4,5-Trihydroxy-trans- stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signalling. Antiviral Res 2004; 63 (2): 85-95
23. Naesens L, Bonnafous P, Agutb H, De Clercq E. Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J Clin Virol 2006; 37 (Suppl. 1): S69-S75.
24. Boone SA, Gerba CP. Significance of fomites in the spread of respiratory and enteric viral disease. Appl Environ Microbiol 2007; 73 (6): 1687-1696.
25. Hayashi S, Hogg JC. Adenovirus infections and lung disease. Curr Opin Pharmacol 2007; 7 (3): 237-243.
26. Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health 2005; 59 (7): 586-590.
27. Gray GC, McCarthy T, Lebeck MG et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis 2007; 45 (9): 1120-1131.